Micell Technologies Enrolls First Patient In DESSOLVE I First-In-Human Study Of MiStent DES

Published: Nov 30, 2010

Medical News Today -- Micell Technologies,â„¢ Inc. announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStentâ„¢ Drug Eluting Coronary Stent System (MiStent DES).

Back to news